Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma

Extracorporeal photopheresis in Sézary syndrome: hematologic parameters as predictors of response

“…In our study, 13 of 23 patients (57%) were classified as responders (more than 25% reduction in skin score from baseline) at 3, 6, 9, or 12 months. This compares with a complete or partial response (more than 50% reduction in skin score from baseline) rate of 33% reported by Vonderheid et al 9 and a previous study from our own group 8 that reported 53% of patients achieved more than 25% reduction in skin score from baseline. The latter study included 11 of the patients involved in this study; the other patients were not included in this study because of incomplete laboratory data or concurrent chemotherapy during treatment with ECP.…”

“…[1][2][3][4][5][6] However, our response rates were consistent with more recent studies that have demonstrated T-cell clones in all or most patients treated. 8,9 Edelson et al 1 classified their patients on the basis of reduction in skin score as follows: responders had a 25% or more reduction in skin score from baseline, whereas those with a less than 25% reduction in skin score from baseline were classified as treatment failures or as unchanged. On this basis, Edelson et al 1 reported that 83% of patients with erythrodermia responded to photopheresis.…”

“…The efficacy of ECP in CTCL was first reported by Edelson et al in 1987. 1 Since then, studies have reported the therapeutic benefit of ECP in CTCL, [2][3][4][5][6][7][8][9][10] though the response data have been variable. 11 This is thought to result from differences in the entry criteria, patient selection, and intervals between diagnosis and treatment.…”

Evidence for an oncogenic role of AHI-1 in Sezary syndrome, a leukemic variant of human cutaneous T-cell lymphomas

“…Consistent with this finding, elevated IL-2 receptor expression has been reported to correlate well with disease states as it is highly increased in advanced CTCL as reported previously. 43,44 Interestingly, our studies revealed that AHI-1 transcript levels were elevated in CD4 þ CD7 À cells from patients with typical SS (SS-2 group); this elevation is not found in similarly purified normal T-cell from healthy individuals or in atypical patients with a low content of leukemic Sezary cells. The highest expression of AHI-1 occurred in a patient (No.…”

Fotoféresis en el tratamiento de Síndrome de Sézary: Caso clínico

“…Sin embargo, son pocos los estudios que han evaluado la efectividad de la FEC como monoterapia. La respuesta, definida como mejoría > 50% del compromiso cutáneo, es aproximadamente de 25% [18][19][20][21][22] . El promedio de respuesta completa en este grupo fue cercana a 10%.…”